share_log

HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $83

Benzinga ·  Aug 2 17:21  · Ratings

HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $92 to $83.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment